. 2023 Nov 1;23:751. doi: 10.1186/s12879-023-08745-4

Table 4.

Sex and country representation in the authorship of evidence supporting the 2021 SSC recommendations

Recommendation	First Author Sex: n (%)	First Author Country Income* n (%)	First Author Country Region** n (%)	Last Author Sex, n (%)	Last Author Country Income, n (%)	Last Author Country Region, n (%)
Screening and Early Treatment (n = 30)	Males: 24 (80%) Females: 5 (17%) Unknown: 1 (3%)	High: 23 (77%) UM: 3 (10%) LM: 1 (3%) Low: 3 (10%)	EAP: 1 (3%) ECA: 8 (27%) LAC: 5 (17%) MENA: 0 (0%) NA: 13 (43%) SA: 0 (0%) SSA: 3 (10%)	Males: 23 (77%) Females: 7 (23%)	High: 26 (87%) UM: 3 (10%) LM: 0 (0%) Low: 1 (3%)	EAP: 0 (0%) ECA: 12 (40%) MENA: 0 (0%) NA: 13 (43%) SA: 0 (0%) SSA: 1 (3%) LAC: 4 (14%)
Infection (n = 126)	Males: 84 (67%) Females: 29 (23%) Unknown: 13 (10%)	High: 116 (92%) UM: 6 (5%) LM: 2 (2%) Low: 2 (2%)	EAP: 22 (17%) ECA: 47 (37%) LAC: 5 (4%) MENA: 4 (3%) NA: 46 (37%) SA: 0 (0%) SSA: 2 (2%)	Males: 94 (75%) Females: 20 (16%) Unknown: 12 (9%)	High: 118 (94%) UM: 4 (3%) LM: 1 (1%) Low: 0 (0%) Unknown: 3 (2%)	EAP: 17 (14%) ECA: 47 (37%) LAC: 4 (3%) MENA: 4 (3%) NA: 51 (41%) SA: 0 (0%) SSA: 0 (0%) Unknown: 3 (2%)
Hemodynamic Management (n = 47)	Males :39 (83%) Females: 7 (15%) Unknown: 1 (2%)	High: 41 (87%) UM: 2 (4%) LM: 3 (7%) Low: 1 (2%)	EAP: 5 (11%) ECA: 13 (28%) LAC: 2 (4%) MENA: 1 (2%) NA: 23 (49%) SA: 1 (2%) SSA: 2 (4%)	Males: 34 (72%) Females: 10 (21%) Unknown: 3 (7%)	High: 42 (89%) UM: 2 (4%) LM: 3 (7%) Low: 0 (0%)	EAP: 5 (11%) ECA: 13 (28%) LAC: 2 (4%) MENA: 1 (2%) NA: 24 (51%) SA: 1 (2%) SSA: 1 (2%)
Ventilation (n = 41)	Males: 36 (88%) Females: 5 (12%)	High: 36 (88%) UM: 5 (12%) LM: 0 (0%) Low: 0 (0%)	EAP: 1 (2%) ECA: 17 (42%) LAC: 5 (12%) MENA: 0 (0%) NA: 18 (44%) SA: 0 (0%) SSA: 0 (0%)	Males: 38 (93%) Females: 2 (5%) Unknown: 1 (2%)	High: 36 (88%) UM: 4 (10%) LM: 0 (0%) Low: 0 (0%) Unknown: 1 (2%)	EAP: 0 (0%) ECA: 21 (51%) LAC: 4 (10%) MENA: 0 (0%) NA: 15 (37%) SA: 0 (0%) SSA: 0 (0%) Unknown: 1 (2%)
Additional therapies (n = 36)	Males: 29 (81%) Females: 7 (19%)	High: 33 (92%) UM: 1 (3%) LM: 2 (5%) Low: 0 (0%)	EAP: 4 (11%) ECA: 17 (47%) MENA: 1 (3%) NA: 11 (30%) SA: 2 (6%) SSA: 0 (0%) LAC: 1 (3%)	Males: 29 (80%) Females: 6 (17%) Unknown: 1 (3%)	High: 33 (92%) UM: 1 (3%) LM: 2 (5%) Low: 0 (0%)	EAP: 2 (6%) ECA: 18 (50%) MENA: 1 (3%) NA: 12 (33%) SA: 2 (6%) SSA: 0 (0%) LAC: 1 (3%)
Long-term Outcomes/ Goals of Care (n = 83)	Males: 46 (55%) Females: 35 (42%) Unknown: 2 (3%)	High: 82 (99%) UM: 1 (1%) LM: 0 (0%) Low: 0 (0%)	EAP: 7 (8%) ECA: 30 (36%) MENA: 0 (0%) LAC: 0 (0%) NA: 46 (55%) SA: 0 (0%) SSA: 0 (0%)	Males: 46 (55%) Females: 35 (42%) Unknown: 2 (3%)	High: 82 (99%) UM: 1 (1%) LM: 0 (0%) Low: 0 (0%)	EAP: 7 (8%) ECA: 30 (36%) MENA: 0 (0%) LAC: 0 (0%) NA: 46 (55%) SA: 0 (0%) SSA: 0 (0%)

Recommendation

First Author
Sex: n (%)

First Author
Country Income*
n (%)

First Author
Country Region**
n (%)

Last Author
Sex, n (%)

Last Author
Country Income,
n (%)

Last Author
Country Region,
n (%)

Screening and Early Treatment

(n = 30)

Males: 24 (80%)

Females: 5 (17%)

Unknown: 1 (3%)

High: 23 (77%)

UM: 3 (10%)

LM: 1 (3%)

Low: 3 (10%)

EAP: 1 (3%)

ECA: 8 (27%)

LAC: 5 (17%)

MENA: 0 (0%)

NA: 13 (43%)

SA: 0 (0%)

SSA: 3 (10%)

Males: 23 (77%)

Females: 7 (23%)

High: 26 (87%)

UM: 3 (10%)

LM: 0 (0%)

Low: 1 (3%)

EAP: 0 (0%)

ECA: 12 (40%)

MENA: 0 (0%)

NA: 13 (43%)

SA: 0 (0%)

SSA: 1 (3%)

LAC: 4 (14%)

Infection

(n = 126)

Males: 84 (67%)

Females: 29 (23%)

Unknown: 13 (10%)

High: 116 (92%)

UM: 6 (5%)

LM: 2 (2%)

Low: 2 (2%)

EAP: 22 (17%)

ECA: 47 (37%)

LAC: 5 (4%)

MENA: 4 (3%)

NA: 46 (37%)

SA: 0 (0%)

SSA: 2 (2%)

Males: 94 (75%)

Females: 20 (16%)

Unknown: 12 (9%)

High: 118 (94%)

UM: 4 (3%)

LM: 1 (1%)

Low: 0 (0%)

Unknown: 3 (2%)

EAP: 17 (14%)

ECA: 47 (37%)

LAC: 4 (3%)

MENA: 4 (3%)

NA: 51 (41%)

SA: 0 (0%)

SSA: 0 (0%)

Unknown: 3 (2%)

Hemodynamic Management

(n = 47)

Males :39 (83%)

Females: 7 (15%)

Unknown: 1 (2%)

High: 41 (87%)

UM: 2 (4%)

LM: 3 (7%)

Low: 1 (2%)

EAP: 5 (11%)

ECA: 13 (28%)

LAC: 2 (4%)

MENA: 1 (2%)

NA: 23 (49%)

SA: 1 (2%)

SSA: 2 (4%)

Males: 34 (72%)

Females: 10 (21%)

Unknown: 3 (7%)

High: 42 (89%)

UM: 2 (4%)

LM: 3 (7%)

Low: 0 (0%)

EAP: 5 (11%)

ECA: 13 (28%)

LAC: 2 (4%)

MENA: 1 (2%)

NA: 24 (51%)

SA: 1 (2%)

SSA: 1 (2%)

Ventilation

(n = 41)

Males: 36 (88%)

Females: 5 (12%)

High: 36 (88%)

UM: 5 (12%)

LM: 0 (0%)

Low: 0 (0%)

EAP: 1 (2%)

ECA: 17 (42%)

LAC: 5 (12%)

MENA: 0 (0%)

NA: 18 (44%)

SA: 0 (0%)

SSA: 0 (0%)

Males: 38 (93%)

Females: 2 (5%)

Unknown: 1 (2%)

High: 36 (88%)

UM: 4 (10%)

LM: 0 (0%)

Low: 0 (0%)

Unknown: 1 (2%)

EAP: 0 (0%)

ECA: 21 (51%)

LAC: 4 (10%)

MENA: 0 (0%)

NA: 15 (37%)

SA: 0 (0%)

SSA: 0 (0%)

Unknown: 1 (2%)

Additional therapies

(n = 36)

Males: 29 (81%)

Females: 7 (19%)

High: 33 (92%)

UM: 1 (3%)

LM: 2 (5%)

Low: 0 (0%)

EAP: 4 (11%)

ECA: 17 (47%)

MENA: 1 (3%)

NA: 11 (30%)

SA: 2 (6%)

SSA: 0 (0%)

LAC: 1 (3%)

Males: 29 (80%)

Females: 6 (17%)

Unknown: 1 (3%)

High: 33 (92%)

UM: 1 (3%)

LM: 2 (5%)

Low: 0 (0%)

EAP: 2 (6%)

ECA: 18 (50%)

MENA: 1 (3%)

NA: 12 (33%)

SA: 2 (6%)

SSA: 0 (0%)

LAC: 1 (3%)

Long-term Outcomes/

Goals of Care

(n = 83)

Males: 46 (55%)

Females: 35 (42%)

Unknown: 2 (3%)

High: 82 (99%)

UM: 1 (1%)

LM: 0 (0%)

Low: 0 (0%)

EAP: 7 (8%)

ECA: 30 (36%)

MENA: 0 (0%)

LAC: 0 (0%)

NA: 46 (55%)

SA: 0 (0%)

SSA: 0 (0%)

Males: 46 (55%)

Females: 35 (42%)

Unknown: 2 (3%)

High: 82 (99%)

UM: 1 (1%)

LM: 0 (0%)

Low: 0 (0%)

EAP: 7 (8%)

ECA: 30 (36%)

MENA: 0 (0%)

LAC: 0 (0%)

NA: 46 (55%)

SA: 0 (0%)

SSA: 0 (0%)

*Based on the World Bank classification of countries by income to the following: High, Upper Middle (UP), Lower-Middle (LM), and Low

**Based on the World Bank classification of countries by region to the following: East Asia Pacific (EAP), Europe and Central Asia (ECA), Latin America Caribbean (LAC) Middle East and North Africa (MENA), North America (NA), South Asia (SA), and Sub-Saharan Africa (SSA).